A new era of stroke prevention in atrial fibrillation: comparing a new generation of oral anticoagulants with warfarin

International Archives of Medicine

Bruce S Stambler¹ 

[1] Division of Cardiovascular Medicine, University Hospitals Case Medical Center, Case Western Reserve University, 11100 Euclid Avenue, Cleveland OH 44106, USA

关键词: Edoxaban;    Apixaban;    Rivaroxaban;    Dabigatran;    Warfarin;    Anticoagulation;    Bleeding;    Hemorrhage;    Stroke;    Atrial fibrillation;   

Others  :  802839
DOI  :  10.1186/1755-7682-6-46

 received in 2013-06-07, accepted in 2013-10-06,  发布年份 2013

【 摘 要 】

Traditionally, warfarin has been used to prevent stroke in patients with atrial fibrillation (AF), but data from large, multinational, prospective, randomized studies suggest that novel oral anticoagulants (NOACs) may be suitable alternatives. These include the direct thrombin inhibitor dabigatran and the factor Xa inhibitors rivaroxaban, apixaban, and edoxaban. These data showed that dabigatran 150 mg twice daily was more effective at preventing stroke than warfarin, with similar rates of major bleeding, while rivaroxaban 20 mg once daily was noninferior to warfarin, with no difference in major bleeding rates. In addition, apixaban 5 mg twice daily was shown to be superior to warfarin for preventing stroke, with lower bleeding rates. Currently, edoxaban is still in clinical trials. NOACs offer more predictable anticoagulant effects than warfarin and do not require regular monitoring; however, different NOACs are associated with varied drug interactions and limitations related to use in certain patient populations. Overall, the clinical data suggest that these novel agents will offer new options for stroke prevention in patients with AF.

【 授权许可】

   
2013 Stambler; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22(8):983-988.
• [2]Passel JS, D’Vera C: February 11, 2008. U.S. population projections: 2005–2050, Pew Research Center. 2008. http://pewhispanic.org/files/reports/85.pdf webcite
• [3]Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS: 2011 ACCF/AHA/HRS focused updated incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011, 57(11):e101-e198.
• [4]Kannel WB, Benjamin EJ: Status of the epidemiology of AF. Med Clin North Am 2008, 92(1):17-40.
• [5]Dulli DA, Stanko H, Levine RL: Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology 2003, 22(2):118-123.
• [6]Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D’Agostino RB: Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996, 27(10):1760-1764.
• [7]Hughes M, Lip GY: Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008, 99(2):295-304.
• [8]Stroke Risk in Atrial Fibrillation Working Group: Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007, 69(6):546-554.
• [9]Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ: Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285(22):2864-2870.
• [10]Hart RG, Pearce LA, Aguilar MI: Meta-analysis: anticoagulant therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146(12):857-867.
• [11]Gattellari M, Worthington JM, Zwar NA, Middleton S: Barriers to the use of anticoagulation for non-valvular atrial fibrillation (NVAF): a representative survey of Australian family physicians. Stroke 2007, 39(1):227-230.
• [12]Gage BF, Boechler M, Doggette AL, Fortune G, Flaker GC, Rich MW, Radford MJ: Adverse outcomes and predictors of underuse of anticoagulant therapy in Medicare beneficiaries with chronic atrial fibrillation. Stroke 2000, 31(4):822-827.
• [13]Reynolds MR, Shah J, Essebag V, Olshansky B, Friedman PA, Hadjis T, Lemery R, Bahnson TD, Cannom DS, Josephson ME, Zimetbaum P: Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. Am J Cardiol 2006, 97(4):538-543.
• [14]Lamassa M, Di Carlo A, Pracucci G, Basile AM, Trefoloni G, Vanni P, Spolveri S, Baruffi MC, Landini G, Ghetti A, Wolfe CD, Inzitari D: Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 2001, 32(2):392-398.
• [15]Baker WL, Cios DA, Sander SD, Coleman CI: Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 2009, 15(3):244-252.
• [16]Coumadin® (warfarin sodium) tablets: prescribing information. http://packageinserts.bms.com/pi/pi_coumadin.pdf webcite
• [17]Schulman S, Beyth RJ, Kearon C, Levine MN, American College of Chest Physicians: Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(6):257S-298S.
• [18]Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS: The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009, 151(5):297-305.
• [19]Hylek EM, Skates SJ, Sheehan MA, Singer DE: An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996, 335(8):540-546.
• [20]Landefeld CS, Goldman L: Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989, 87(2):144-152.
• [21]Pisters R, Lane DA, Nieuwlaat R, De Vos CB, Crijns HJ, Lip GY: A novel user friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey. Chest 2010, 138(5):1093-1100.
• [22]Olesen JB, Lip GYH, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, Raunsø J, Tolstrup JS, Hansen PR, Gislason GH, Torp-Pedersen C: Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost 2011, 106(4):739-749.
• [23]Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D, Brandt JT: Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998, 144(5 Suppl):445S-469S.
• [24]Weitz JI, Hirsh J, Samama MM: New anticoagulant drugs: the Seventh ACCP Conference on Anticoagulants and Thrombolytic Therapy. Chest 2004, 126(3 Suppl):265S-286S.
• [25]Eriksson BI, Quinlan DJ, Weitz JI: Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009, 48(1):1-22.
• [26]Camm AJ, Bounameaux H: Edoxaban: a new oral direct factor Xa inhibitor. Drugs 2011, 71(12):1503-1526.
• [27]Van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A: Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010, 103(6):1116-1127.
• [28]Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D: Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2009, 37(5):1056-1064.
• [29]Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, Reeves RA, Lacreta F: Apixaban, an oral, direct factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 2013, 75(2):476-487.
• [30]Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE, Maxwell BD, Chen SY, He K, Goosen TC, Humphreys WG, Grossman SJ: In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 2010, 38(3):448-458.
• [31]Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, Chan AK, James A, Moll S, Ortel TL, Van Cott EM, Ansell J: Guidance on the emergent reversal of oral thrombin and factor Xa. Am J Hematol 2012, 87(Suppl 1):S141-S145.
• [32]Ridgefield CT, Boehringer Ingelheim Pharmaceuticals, Inc: Pradaxa® (dabigatran etexilate mesylate) capsules: prescribing information. 2011. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf webcite
• [33]Raritan NJ, Janssen Pharmaceuticals, Inc: Xarelto® (rivaroxaban) tablets prescribing information. 2011. http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf#zoom=100 webcite
• [34]Princeton NJ, Bristol-Myers Squibb Company: Eliquis® (apixaban) tablets prescribing information. 2012. http://packageinserts.bms.com/pi/pi_eliquis.pdf webcite
• [35]Matsushima N, Lee F, Sato T, Weiss D, Mendel J: Absolute bioavailability of edoxaban in healthy subjects. AAPS J 2011, 13(Suppl 2):T2362.
• [36]Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, Kunitada S: Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010, 50(7):743-753.
• [37]Mendel J, Zahir H, Ridout G, Noveck R, Lee F, Chen S, Zhang G, Shi M: Drug-drug interaction studies of cardiovascular drugs (amiodarone, digoxin, quinidine, atorvastatin and verapamil) involving p-glycoprotein (P-GP), and efflux transporter, on the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban, an oral factor Xa inhibitor. JACC 2011, 57(Suppl):E1510.
• [38]Masumoto H, Yoshigae Y, Watanabe K, Takakusa H, Okazaki O, Izumi T: In vitro metabolism of edoxaban and the enzymes involved in the oxidative metabolism of edoxaban. AAPS J 2010, 12(Suppl 2):W4308.
• [39]Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J: Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos 2012, 40(12):2250-2255.
• [40]European Medicines Agency: CHMP Assessment Report for Xarelto. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000944/WC500057122.pdf webcite
• [41]Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361(12):1139-1151.
• [42]Bhagirath VC, O’Malley L, Crowther MA: Management of bleeding complications in the anticoagulated patient. Semin Hematol 2011, 48(4):285-294.
• [43]Wang X, Tirucherai G, Pannacciulli N, Wang J, Elsrougy A, Teslenko V, Chang M, Zhang D, Frost C: Effect of activated charcoal on the pharmacokinetics of apixaban in healthy subjects. Clin Pharmacol Ther 2012, 91(Suppl 1):S41.
• [44]Van Ryn J, Sieger P, Kink-Eiband M, Gansser D, Clemens A: Adsorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitro. Blood 2009, 114:22-1065.
• [45]Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G: Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59–7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005, 78(4):412-421.
• [46]Battinelli EM: Reversal of new oral anticoagulants. Circulation 2011, 124(14):1508-1510.
• [47]Chang M, Yu Z, Shenker A, Wang J, Pursley J, Boyd R, LaCreta F, Frost C: Apixaban pharmacokinetics and pharmacodynamics in subjects with renal impairment. Clin Pharmacol Drug Dev 2012, 1(4):185-186.
• [48]Wang X, Song Y, Tirucherai G, Ehlgen A, Wang J, Chang M, Zhang D, Frost C: Apixaban pharmacokinetics in subjects with end-stage renal disease on hemodialysis. Clin Pharmacol Drug Dev 2012, 1(4):187.
• [49]Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, et al.: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365(11):981-992.
• [50]Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O’Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S, AVERROES Steering Committee and Investigators: Apixaban in patients with atrial fibrillation. N Engl J Med 2011, 364(9):806-817.
• [51]Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E: Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010, 160(4):635-641.
• [52]Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKET AF Investigators: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365(10):883-891.
• [53]Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L: Newly identified events in the RE-LY trial. N Engl J Med 2010, 363(19):1875-1876.
• [54]Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA, Ezekowitz MD, Yusuf S: Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012, 43(6):1511-1517.
• [55]Dabigatran etexilate mesylate capsules: Advisory Committee Briefing Document. 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM226009.pdf webcite
• [56]Granger CB, Alexander JH, Hanna M, Wang J, Mohan P, Lawrence J, Hylek E, Ansell JE, Wallentin L: Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial. Eur Heart J 2012, 33:685-686.
• [57]Pradaxa® (dabigatran etexilate mesylate): Drug safety communication – safety review of post-market reports of serious bleeding events. 2011. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm282820.htm webcite
• [58]Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F, RE-ALIGN Investigators: Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013, 369(13):1206-1214.